MedTrace Logo

Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy

NCT00099970 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2008-08-05

No results posted yet for this study

Summary

This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) that is required for the establishment of new blood vessels during tumor growth, a process known as angiogenesis.

Conditions

Interventions

DRUG

M200 (volociximab) in Combination with Dacarbazine (DTIC)

Sponsors & Collaborators

  • PDL BioPharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Steven J. O'Day, M.D. · Cancer Institute Medical Group, Inc.

  • John Kirkwood, M.D. · University of Pittsburgh

  • Agop Y. Bedikian, MD · M.D. Anderson Cancer Center

  • Antoni Ribas, MD · University of California, Los Angeles

  • Colin P. Curran, M.D. · Palmetto Hematology Oncology, P.C.

  • Andres Forero, M.D. · University of Alabama at Birmingham

  • Lee Cranmer, M.D. · University of Arizona

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Completion
2006-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00099970 on ClinicalTrials.gov